About this trial
Advanced heart failure, affecting 7 million Americans, has multiple causes and results in greatly increased risk of disability and death. A major problem is sudden cardiac death, when the damaged heart develops an abnormal pattern of electrical conduction that can result in cessation of heart activity. While placement of an Implantable Cardioverter-Defibrillator (ICD) in a patient's chest can help prevent sudden cardiac death, these devices have several important downsides. This protocol focuses on development of a digital decision aid that helps heart failure patients make informed decisions that balance the benefits and downsides of ICD placement. This protocol covers the use of participant surveys, focus groups, and interviews to obtain the needed background information to guide the development of this digital tool, which will be subsequently tested against usual care in a randomized clinical trial. The study design is best described as a mixed methods evaluation and refinement of a digital app to improve ICD decision-making. In the future, the present protocol will be modified to create a new protocol that covers the needed human subjects requirements for performance of this clinical trial.
Eligibility criteria
Qualifiers
Meets or approximates minimal criteria for primary prevention ICD placement. ● Left Ventricular Ejection Fraction (LVEF) <35%.
Patients with severe ischemic dilated cardiomyopathy and underlying NYHA
Class II or III Heart Failure, OR, Patients with severe nonischemic dilated cardiomyopathy and underlying NYHA Class II or III Heart Failure.
Age ≥ 70 years old.
Disqualifiers
Past ICD implantation (not including pacemakers).
Any indication for secondary prevention of SCD via ICD implantation.
History of mechanical valve replacement.
History of recent myocardial infarction within the last 40 days.
Trial design
Treatments tested in this trial
- Online, patient-facing decision-making aid (app) with personalized risk information.
- Implantable Cardioverter Defibrillator (ICD)
- Online, patient-facing decision-making app without personalized risk information.
Treatment groups
Sponsors and collaborators
Stanford University
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
University of California, San Francisco
Collaborator
East Carolina University
Collaborator